Tumor Microenvironment Bootcamp

Tuesday, November 16, 2021

9.30 – 2.30 EST |  6.30 – 11.30 PST

* Please note that the following agenda timings are Eastern Time.
For Pacific Times, please download the full event guide here

9:30 am | Coffee Networking Session

10:00 am Chair’s Opening Remarks

  • Erika Von Euw Senior Director, Translational Research, T-Cure Bioscience

Analyze the Benefits of Targeting Hot Tumors with Cell Immunotherapy

10:10 am Determine Optimal Cells for Tumor Infiltration


  • Analyse the differentiation state most optimal to effectively infiltrate tumors
  • Examine the chemokines produced by tumors to recruit immune cells, outlining which cell types have the best chance of recruitment
  • Consider the potential of macrophages with their inherent ability to traffic and thrive in the TME

10:40 am Review Hot Tumors with Best Chance of Immunotherapy Success


  • Analyze the tumor microenvironments of immunogenic solid tumor models
  • Outline TCR-NK ability to target solid tumors, addressing the immunosuppressive environment and heterogenous targeting issues

11:10 am Discussion session: What Tumors Should We Be Targeting?


  • Compare tumor types which are inherently inflammatory to those which have a strong capsular shield, to determine which solid tumor indications require additional pressure to home cell therapies to the tumor
  • Outline biomarkers of disease-specific tumor microenvironments to characterize and map tumor biology
  • Determine which checkpoints are most important across tumor types, how do they vary across tumors?

11:50 am

Speed Networking & Refreshment Break


Like speed dating, but for business! Turn on your camera and connect with delegates of the Bootcamp. This is your chance to meet with colleagues who are dedicated to exploring the tumor microenvironment, your random connection could lead to your next collaboration!

Overcome the Limtations of Cold Tumor Microenvironments

12:45 pm Address Limitations of Solid Tumor CAR T Cell Therapies


  • Outline strategies to address hurdles through combination therapies in preclinical models
  • Forward thinking into building ongoing clinical trials

1:15 pm CAR-M: Targeting Solid Tumors and Remodeling Their TME


  • Characterize the immunosuppressive cell make-up and review the role of CAR-macrophages in remodeling the TME

1:45 pm Targeting Minimal Residual Disease in Solid Tumors: Challenges and Opportunities

  • Ahmed Ahmed Professor of Gynaecological Oncology, University of Oxford


• Understand why targeting minimal residual disease in solid tumors provides a significant therapeutic opportunity
• Outline the genomic and transcriptomic make up of MRD in ovarian cancer
• Describe how MRD is likely to interact with the tumor microenvironment

2:15 pm Penetrating the Extracellular Matrix to Access Tumor Cells


  • Understand the making of the tumor matrix and explore current approaches to overcome the dense fibrotic material, including
    targeting Fibroblast Activation Protein with CAR-T cells to disrupt the microenvironment
  • Arming strategies to overcome tumor inaccessibility

2:45 pm Overcoming Solid Tumor Challenges with ARTEMIS® Antibody Redirected T-Cell Therapy

  • Cheng Liu Founder & CEO, Eureka Therapeutics, Inc.


  • Designing ARTEMIS® Antibody TCR (AbTCR) T-cells to address the major hurdles in treating solid tumor
  • Infiltrating into solid tumor under immunosuppressive microenvironment
  • Targeting Alpha-fetoprotein (AFP) and Glypican 3 (GPC3) in advanced hepatocellular carcinoma (HCC)
  • Demonstrating superior safety and efficacy profile of ARTEMIS® T-cells

3:15 pm Chair’s Closing Remarks

  • Erika Von Euw Senior Director, Translational Research, T-Cure Bioscience

3:20 pm | Close of Bootcamp Day